5 Ways Gilead Sciences Could Spend Its Cash Hoard
Gilead Sciences (NASDAQ: GILD) has a growth problem.
Long known for its enormous HIV franchise and market share, Gilead branched out into hepatitis C (HCV) in 2012. While that market provided plenty of growth in 2014, payer restrictions and the fact that Gilead had cured most of the sickest patients left management searching for new ways to create shareholder value by 2016.
Gilead has a lot of money to do just that: $34.6 billion in cash and short- and long-term investments. Here are a few ways it could use that cash hoard.
Source: Fool.com
Gilead Sciences Inc Aktie
Eine klare Neigung zu Buy-Einschätzungen bei Gilead Sciences Inc, ohne Sell-Einschätzungen.
Ein Kursziel von 85 € für Gilead Sciences Inc zeigt ein leicht positives Potenzial im Vergleich zum aktuellen Kurs von 71.02 €.